Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer.
about
Engineered SIRPĪ± variants as immunotherapeutic adjuvants to anticancer antibodies.HER2 expression beyond breast cancer: therapeutic implications for gynecologic malignancies4-1BB Agonists: Multi-Potent Potentiators of Tumor ImmunityAnalyses of CD20 monoclonal antibody-mediated tumor cell killing mechanisms: rational design of dosing strategiesClinical significance of tumor-infiltrating lymphocytes in breast cancer4-1BB agonism: adding the accelerator to cancer immunotherapyRecent advances in the development of anti-HER2 antibodies and antibody-drug conjugatesMechanisms of action of therapeutic antibodies for cancerRecent advances in mantle cell lymphoma: report of the 2012 Mantle Cell Lymphoma Consortium Workshop.Nimotuzumab Induces NK Cell Activation, Cytotoxicity, Dendritic Cell Maturation and Expansion of EGFR-Specific T Cells in Head and Neck Cancer PatientsTargeting CD137 enhances the efficacy of cetuximab.Targeting secondary immune responses to cetuximab: CD137 and the outside story.Oncogene withdrawal engages the immune system to induce sustained cancer regression.An essential role for the immune system in the mechanism of tumor regression following targeted oncogene inactivation.New Immunotherapy Strategies in Breast Cancer.Combination immunotherapy: a road map.Conformation of the human immunoglobulin G2 hinge imparts superagonistic properties to immunostimulatory anticancer antibodies.Classification of current anticancer immunotherapiesAgonist antibodies to TNFR molecules that costimulate T and NK cellsNKT cell-targeted vaccination plus anti-4-1BB antibody generates persistent CD8 T cell immunity against B cell lymphoma.NK cell-based immunotherapies in Pediatric Oncology.Present and Future of Allogeneic Natural Killer Cell TherapyFocusing and sustaining the antitumor CTL effector killer response by agonist anti-CD137 mAb.Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cellsIntroduction to monoclonal antibodies.Molecular Mechanisms of Trastuzumab-Based Treatment in HER2-Overexpressing Breast CancerImmunomodulation via Chemotherapy and Targeted Therapy: A New Paradigm in Breast Cancer Therapy?Signaling pathway and dysregulation of PD1 and its ligands in lymphoid malignancies.The Role of Adaptive Immunity in the Efficacy of Targeted Cancer TherapiesAntibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells.Hypoxia-induced soluble CD137 in malignant cells blocks CD137L-costimulation as an immune escape mechanism.Adaptive Immune Responses and HER2/neu Positive Breast Cancer.Taxanes enhance trastuzumab-mediated ADCC on tumor cells through NKG2D-mediated NK cell recognition.Targeting breast cancer stem cells with HER2-specific antibodies and natural killer cells.Emerging therapeutic targets in metastatic progression: A focus on breast cancer.Noncanonical roles of the immune system in eliciting oncogene addictionIdentification of CD245 as myosin 18A, a receptor for surfactant A: A novel pathway for activating human NK lymphocytesThe immune system and inflammation in breast cancer.CIMT 2015: The right patient for the right therapy - Report on the 13th annual meeting of the Association for Cancer ImmunotherapyEnhanced interaction between natural killer cells and lung cancer cells: involvement in gefitinib-mediated immunoregulation.
P2860
Q24605057-50D38929-1624-4BA9-8790-79835EAEACA1Q26822730-1A2BB040-747C-42FC-A736-FDA7DB947AB9Q27012963-F2C16E03-F0AA-441D-8239-7F82264EC2A6Q27694769-714A09A2-D18C-4238-9C2A-AD636348E5E2Q28070214-15284449-B9E3-4E74-8FFC-CEF1DCFBB63FQ28079622-ED86E6FD-0505-4E7A-92D7-3E4AD8059C75Q28083123-D344C561-8074-4F08-B6D8-4EC13EA8E3FCQ28385366-88B5B2BE-ED3A-4C44-854D-BF11A21B083AQ30456436-AC8B3C3D-4B42-459A-96E7-59EB432C328AQ33809528-065E661D-E2BE-43F0-A3E2-44342C794B3CQ33872482-EAC76F0B-C145-4ABA-81C6-B31DC148CCC8Q33872496-1539D90C-A2E5-469E-9D2C-45A48E7675C9Q33987633-7DC00FD7-FE5F-4611-97E9-8BAC8CCB8AD8Q34361976-4C549C40-7172-4155-BF7A-69858CA841BAQ34549227-49770032-D5BC-4200-BFC9-3C7EAD363026Q34552128-19BEE1EF-9D99-4D00-A09B-94A03CFA2A82Q34978570-BA3542AD-E86F-4115-BABD-C998E4DFFF89Q35149637-C1292C04-45B0-48D8-A12B-4DB1B10448C5Q35427446-D21CA119-862D-4812-B469-8372B818BB74Q35506745-DAEF5F16-5931-4336-873A-32E1D76FE1A8Q35600975-3E53790D-553A-48D3-841A-94CB46B2C1F4Q35677351-C4EA45D1-B2BF-49DD-8081-C5A5F5B8BD99Q35764479-44273A72-F69C-4F89-B450-B6467DF332B9Q35918911-804489A3-724D-42B7-8EE8-249999FF14CCQ36050008-17E46074-47EF-4E4A-B5AF-F0981F8373B9Q36440214-1E231C3C-A52D-44A3-9969-6D903F583B10Q36449290-16CBB049-E46A-4FA1-B2FE-0592C24D0CA1Q36522770-2DB07B3A-907E-4B54-BF7A-FC9502BC8E02Q36535465-F7AF0977-E1DD-4451-8DA4-B17FF21F88E0Q36539682-53E458DA-6893-4C11-A3BC-966853ADC87DQ36597479-9CD92895-F769-47BF-BA99-6609113B7A28Q36607857-8990AC7E-C1E4-41F1-ABA3-04EF1AEFE8FFQ36729376-51CC2571-C190-43B9-868D-800967903807Q36758890-925E9DDF-EE8E-4A37-8FB4-92793C2A47E6Q36854062-D6449BF8-2FA4-4E06-8912-E677404FC070Q36931816-68177FF1-DD50-49B8-8BFA-AE7991FD2DB1Q37012676-DA0521AE-2315-4D0B-ADA0-D5EE40915AE5Q37033451-1EAAE1D1-3674-49A0-9720-BE23AED22D3DQ37130209-D2D7853F-4F55-4BCE-90A7-260FA76E234AQ37155165-8F1696B2-ECEA-44B9-815E-BD9682AD2DD5
P2860
Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer.
description
2012 nĆ® lÅ«n-bĆ»n
@nan
2012幓ć®č«ę
@ja
2012幓č«ę
@yue
2012幓č«ę
@zh-hant
2012幓č«ę
@zh-hk
2012幓č«ę
@zh-mo
2012幓č«ę
@zh-tw
2012幓č®ŗę
@wuu
2012幓č®ŗę
@zh
2012幓č®ŗę
@zh-cn
name
Stimulation of natural killer ...... plant models of breast cancer.
@ast
Stimulation of natural killer ...... plant models of breast cancer.
@en
type
label
Stimulation of natural killer ...... plant models of breast cancer.
@ast
Stimulation of natural killer ...... plant models of breast cancer.
@en
prefLabel
Stimulation of natural killer ...... plant models of breast cancer.
@ast
Stimulation of natural killer ...... plant models of breast cancer.
@en
P2093
P2860
P356
P1476
Stimulation of natural killer ...... plant models of breast cancer.
@en
P2093
A Dimitrios Colevas
Debra Czerwinski
Ferenc Scheeren
Frank E Stockdale
Holbrook E Kohrt
Joseph A Mollick
Kipp Weiskopf
Lieping Chen
Matthew J Goldstein
Michael F Clarke
P2860
P304
P356
10.1172/JCI61226
P407
P577
2012-02-13T00:00:00Z